Springhill Fund Asset Management’s Verona Pharma VRNA Stock Holding History

Springhill Fund Asset Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63,499	Closed	-$4.03M	–	19
2025 Q1	$4.03M	Sell	63,499 -71,953	-53%	-$4.3M	19.32%	1
2024 Q4	$6.29M	Buy	+135,452	New	+$5.09M	10.22%	1

Other funds holding VRNA

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Springhill Fund Asset Management's VRNA Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 63,499 shares — an estimated $4.03M sold.

Springhill Fund Asset Management first reported a position in VRNA in Q4 2024 and held it in 2 quarters. The position peaked at $6.29M in Q4 2024. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

Springhill Fund Asset Management reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
Springhill Fund Asset Management sold 63,499 Verona Pharma shares in Q2 2025, an estimated $4.03M.
Springhill Fund Asset Management first reported a position in Verona Pharma in Q4 2024 and held it in 2 quarters.
Springhill Fund Asset Management's Verona Pharma position peaked at $6.29M in Q4 2024.
292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.